Last week, an FDA advisory committee voted in favor of approving Sarepta Therapeutics, Inc.'s SRP-9001 for treating DMD. Sarepta Therapeutics stock has good near-term momentum as the BLA is scheduled ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. A gene therapy technique restored some muscle function for months in patients with a certain type of muscular ...

Thirty marks the spot. Starting at this age, we begin to lose approximately three to eight percent of muscle mass per decade. With it, we also lose strength and mobility. Left unaddressed, this loss ...